Addex Therapeutics - ADR opened higher at $4.60, compared with its previous close of $2.89. In the last trading session, the stock traded between $4.29 and $6.50. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Addex Therapeutics - ADR is now worth
$ 3.41
Resulting in a loss of
$ 96.59 (96.59%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$2.38 (+82.42%)
Day High
$6.50
Day Low
$4.29
Day Open
$4.60
Prev Close
$2.89
Volume
2,18,91,259
1W Return
77.81%
1M Return
72.57%
3M Return
-9.94%
6M Return
-23.15%
1Y Return
-40.16%
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
0.93
PEG Ratio
-
ROE
-74.02%
ROCE
-71.56%
EPS (TTM)
$-0.01
1 Week
77.81%
1 Month
72.57%
3 Months
-9.94%
6 Months
-23.15%
9 Months
-31.71%
Neurosterix closes $105 million Series B for schizophrenia drug NTX-253
Neurosterix closed a $105 million Series B round led by life science investors. Addex Therapeutics holds an 8.5% stake in Neurosterix valued at $18.6 million. Funds will advance NTX-253, a muscarinic M4 PAM, into Phase 2 trials for schizophrenia.
YesterdayAddex Therapeutics appoints Jean-Philippe Rocher as head of pharmaceutical development
Jean-Philippe Rocher appointed as Head of Pharmaceutical Development and Executive Management member. Mikhail Kalinichev steps down as Head of Translational Science to focus on Neurosterix. Rocher previously helped build Addex's chemistry platform and discover Phase II candidates dipraglurant and ADX71149. Addex regained rights to GABAB PAM program from Indivior, with several candidates ready for clinical development.
1mo agoAddex Therapeutics extends cash runway to Q4 2027 after $2.8m raise
Cash runway extended into Q4 2027 following $2.8 million ATM raise. Operating loss narrowed to $1.1 million in H1 2026 from $1.3 million in H1 2025. Full rights to GABAB PAM portfolio regained from Indivior. Neurosterix Phase 1 study for NTX-253 expected to complete in Q4 2026.
1mo agoAddex Therapeutics regains global rights to GABAB PAM portfolio from Indivior
Addex Therapeutics regained full global rights to all GABAB PAM assets from Indivior UK Limited on September 25, 2026. The rights return follows Indivior's R&D rationalization and its parent company's planned merger with Supernus Pharmaceuticals. Addex now holds independent control over candidates for substance use disorders and chronic cough, expanding its GABAB receptor portfolio. The company plans to evaluate strategic options, including seeking new partnerships or advancing programs further before partnering.
1mo agoAddex Therapeutics raises USD 2.8m via ATM, extends runway to Q4 2027
Addex Therapeutics raised USD 2.8 million via ATM offering. Sale involved 437,869 ADSs representing 52.5 million shares. Cash runway extended to fourth quarter of 2027. Outstanding shares increased to 210.3 million post-issue.
2mo agoAddex study highlights mGlu7 role in sleep regulation
Addex Therapeutics published research in the International Journal of Neuropsychopharmacology showing ADX71743 modulates sleep-wake regulation. The study found the compound increased wakefulness and reduced sleep in rats while altering stress-related neurochemistry. These results support the therapeutic potential of mGlu7 inhibition for CNS disorders.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Addex Therapeutics - ADR is now worth
$ 3.41
Resulting in a loss of
$ 96.59 (96.59%)
Note: Past profits do not guarantee future returns.
